Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ

Journal of the National Cancer Institute

Volumn 107, Issue 12, 2015, Pages

  Worni, Mathias ^a,b   Akushevich, Igor ^a   Greenup, Rachel ^a   Sarma, Deba ^a   Ryser, Marc D ^a   Myers, Evan R ^a   Hwang, E Shelley ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE SPECIFIC SURVIVAL; DUCTAL BREAST CARCINOMA IN SITU; FEMALE; HUMAN; HUMAN TISSUE; LUMPECTOMY; MASTECTOMY; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREND STUDY; TUMOR VOLUME; ADJUVANT RADIOTHERAPY; BREAST NEOPLASMS; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMISTRY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; ETHNOLOGY; MODIFIED RADICAL MASTECTOMY; ODDS RATIO; PARTIAL MASTECTOMY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEER PROGRAM; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84959572659     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv263     Document Type: Article

References (35)

1. Barnes NL, Dimopoulos N, Williams KE, et al. The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast. Eur J Surg Oncol. 2014;40(3):249–254.
2. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–178.
3. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
4. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–488.
5. Romero L, Klein L, Ye W, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2004;188(4):371–376.
6. Lee LA, Silverstein MJ, Chung CT, et al. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg. 2006;192(4):416–419.
7. Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443–448.
8. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–3387.
9. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260(1):119–128.
10. Kettritz U, Rotter K, Schreer I, et al. Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study. Cancer. 2004;100(2):245–251.
11. SEER. National Cancer Institute, Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/. Accessed May 17, 2015.
12. Kertai MD, Esper SA, Akushevich I, et al. Preoperative CYP2D6 metabolism-dependent beta-blocker use and mortality after coronary artery bypass grafting surgery. J Thorac Cardiovasc Surg. 2014;147(4):1368–1375.
13. Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45–49.
14. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005.
15. Greenup RA, Peppercorn J, Worni M, et al. Cost implications of the SSOASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer. Ann Surg Oncol. 2014;21(5):1512–1514.
16. El-Tamer MB, Ward BM, Schifftner T, et al. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg. 2007;245(5):665–671.
17. Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002;9(6):543–549.
18. D’Angelo SP, Antonescu CR, Kuk D, et al. High-risk features in radiation-associated breast angiosarcomas. Br J Cancer. 2013;109(9):2340–2346.
19. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–998.
20. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–710.
21. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627–637.
22. Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013;7(5):859–869.
23. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362–1367.
24. Gomez SL, Lichtensztajn D, Kurian AW, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol. 2010;28(10):e155–e157; author reply e158.
25. Feigelson HS, Carroll NM, Weinmann S, et al. Treatment patterns for ductal carcinoma in situ from 2000–2010 across six integrated health plans. Springerplus. 2015;4:24.
26. Zetterlund L, Stemme S, Arnrup H, et al. Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg. 2014;101(5):488–494.
27. Sakr R, Barranger E, Antoine M, et al. Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol. 2006;94(5):426–430.
28. Chen AY, Halpern MT, Schrag NM, et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst. 2008;100(7):462–474.
29. Osako T, Iwase T, Ushijima M, et al. Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ. Cancer Sci. 2014;105(5):576–582.
30. Chin-Lenn L, Mack LA, Temple W, et al. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Ann Surg Oncol. 2014;21(1):66–73.
31. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–1383.
32. Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.
33. Goodwin A, Parker S, Ghersi D, et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2013;11:CD000563.
34. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12(5):686–718.
35. Walker GV, Giordano SH, Williams M, et al. Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries. Int J Radiat Oncol Biol Phys. 2013;86(4):686–693.